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Background: Enzyme-actwatable prodrugs in conjunction 
xvith antibodyPenryrne fusion proteins may enhance the 
anti-tumor- efficacy of antibodies and reduce the toxic side 
effects of conventional chemotherapeuticc. Cephalosporins 
have proven to be highly versatile triggers for the enzymatic 
actlvatlon of such prodrugs. 
Results: A cephem prodrug of taxol (PKOTAX) was syn- 
thesized by substituting the C-3’ position of cephalothin 
with 2’-(y-dminobu~ryl) taxol. Hydrolysis of PROTAX 
by p-lactamCt\e rapidly released 3’-(y-arninobutyryl) taxol 
(Lt’KM = (1.4 k 0.1) s 10” 5-l Mm’). which yielded 
tasol Eollo\\-ing intramolecular displacenicnt. PROTAX is 
inactive in a microtubule asscnibly essay in vitro but has 
similar activity to tax01 following prolonged activation 
with @-lactaniase. PROTAX IS -lo-fold less toxic than 
tasol against SK-8%3 breast tumor cells il l 1Gfrc1 but has 
activity appronchin g that of taxol folloxving prolonged 
activation with J fusion protein conlprising P-lactamase 
fused to a tunior-targeting antibody fragment. 
Conclusions: Tubulin polymerization acti\,ity is abolished 
and cytotosicic is reduced in the PROTAX prodrug 
conlpxed to taxol. Activation of PROTAX by P-lacta- 
nlase follo\vcd by self-immolation restores the activity of 
PROTAX to that of free taxol. 
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Introduction 
The use of enzyme-activatable prodrugs in conjunction 
with antibody-enzyme fusion proteins or conjugates is a 
promising strategy for enhancing the anti-tumor efficacy 
of antibodies and minimizing the toxicity of chemo- 
therapeu tic5 (reviewed in [ 1,2l) Indeed, targeted pro- 
drugs have proven to be much more efficacious than 
corresponding free drugs against human tumor 
xenografttc in nude mice [3-51. 
Our humanized anti-p1 8jHE”’ antibody, humAb4D5-8 
161 was developed as a potential therapy for human 
cancers which overexpress pl 8jHEK2 and has recently 
completed phase II clinical testing for the treatment of 
metastatic breast cancer.This humanized antibody is now 
being used as a building block to design potentially more 
potent immunotherapeutics.To this end we developed a 
fusion protein (dsFv3-P-lactamase) comprising a disul- 
fide-stabilized Fv fragment of humAb4D5-8 fused to 
p-lactamase, RTEM-1, for use in targeted therapy in 
conjunction with cephem-based prodrugs [ 71. 
P-Lactamase is an attractive choice of enzyme for 
prodrug activation because of its high catalytic efficiency 
and broad substrate specificity. Furthermore, there are no 
known similar activities, competing substrates or 
inhibitors endogenous to man. Cephalosporins have 
proven to be highly versatile substrate triggers in the 
construction of enzyme-activatable prodrugs including 
vinca alkaloids [3,8,9], nitrogen mustard drugs IlO-131, a 
carboplatin analog [ 131 and doxorubicin [7,1 -I, 151. 
Additional cephalosporin prodrugs have been described 
in the patent literature, including 5-fluorouracil, h-mer- 
captopurine, 6-thioguanine, methotrexate and mito- 
mycin C [I 6].The cephem moiety is attached to a group 
on the chemotherapeutic agent chosen so that the 
prodrug is less toxic than the drug. Fully active drug (or 
drug analog) is released after P-lactamase-mediated 
cleavage of the p-lactam ring. 
Tax01 is an attractive drug for combining with 
humAb4D-8 since p 1 X5 HE’~2 is overexpressed in -25 ‘% 
of primary human breast and ovarian cancers [I 7,l X] and 
taxol itself is approved in the United States for the treat- 
ment of these cancers. Targeted prodrugs offer a way of 
potentially reducing the toxicities of taxol which include 
myelosuppression, mucositis and peripheral neuropathy 
[I 9,20]. In addition. tnxol is only sparingly soluble and is 
delivered in polyoxyethylated castor oil (Cremaphor EL) 
which has its own associated toxicities including hyper- 
sensitivity [ 19,20]. The biological activity of taxol in pro- 
moting and stabilizing the assembly of microtubulcs 
requires a free C-3’ hydroxyl (reviewed in [Zl]). In COII- 
trast the C-7 hydroxyl of taxol can be modified with 
retention of biological activity [2 11 .These structure-func- 
tion properties of taxol have been used by others in the 
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synthesis of water-soluble derivatives 122-241 including 
prodrugs that are efficiently activated in human serum 
[25]. Here we describe the synthesis and preliminary 
characterization of PROTAX, a cephem prodrug of taxol 
that is activatable by p-lactamase. 
Results and discussion 
Chemical synthesis of PROTAX 
The activated cephem sulfoxide, compound 4, has been 
coupled to a primary amine in a vinca alkaloid [9] or in 
doxorubicin [7,14] to create corresponding cephem 
prodrugs. We synthesized compound 4 [7] with minor 
modifications of the original method [9] but were not 
successful in coupling it to the C-2’ hydroxyl of taxol 
(compound 1). It was possible, however, to modify the 
C-2’ hydroxyl of taxol with an aminobutyryl linker to 
give compound 3, the taxol linker [26], and couple this 
to compound 4 to yield compound 5, the taxol 
prodrug, PROTAX (Fig. 1). 
Fig. 1. Synthesis and activation of 
PROTAX. PROTAX was synthesized 
from taxol and subsequently acti- 
vated to taxol using the following 
conditions: (i) dicyclocarbodiimide, 
N-CBz-y-aminobutyric acid; (ii) 10 % 
Pd/C, formic acid, MeOH; (iii) 0.1 N 
NaHCO,; (iv) 8-lactamase or dsFv3- 
f3-lactamase in PBS, pH 7.4; (v) PBS, 
pH 7.4. Compound 4 191 was 
synthesized as previously described 171. 
Activation of PROTAX by p-lactamase 6d-L 
16h ~Taxo~ n 
PROTAX is rapidly hydrolyzed by both free p-lactamase 
and the tumor-targeting fusion protein, dsFv3- 
P-lactamase, to release taxol linker: kcat/Krvl = (1.4 ? 0.1) 
x 105 s-l M-l and (6.3 2 1.3) x 10” s-’ M-‘, respectively. 
The second activation step (reaction v in Fig. 1) involving 
self-immolation of taxol linker to release free taxol is slow 
compared to the first enzymatic cleavage step (reaction Fig. 2. HPLC analysis of PROTAX activation. PROTAX (70.4 PM) 
iv), as judged by HPLC (Fig. 2). Reaction v is approxi- was hydrolyzed at 37 ‘-‘C in the presence of 180 nM p-lactamase 
mately 50 % complete after 6 h and is approaching in PBS, pH 7.4, for varying times prior to analysis by reverse 
completion after 16 h. phase HPLC (C,, column, Vydac, Hesperia, CA) using 30-90 % 
(v/v) acetonitrile, 0.1 % (v/v) TFA in Hz0 as the mobile phase. 
Peaks were identified as taxol-linker or taxol on the basis of 
Cephem prodrugs including PROTAX are prone to electrospray mass spectrometry: taxol m/e 939.5 CM+), expected 
slow non-enzymatic hydrolysis (a property of their 939.4; taxol linker m/e 854.4 (M+H+), expected 853.9. 
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Fig. 3. Microtubule-assembly assay. Polymerization of bovine 
brain tubulin (1 mg ml-‘) at (35 + 1) “C was monitored by follow- 
ing the absorbance at 340 nm in the presence of 11 FM taxol (III), 
or 1 1 FM PROTAX before (0) or after (0) activation with 180 nM 
p-lactamase for 18 h, or in the absence of further additions (W). 
parent cephalosporins [271), which probably sets an 
upper limit on the ratio of toxicity of prodrug to drug. 
The toxicity profile of PROTAX in LJ~VO may be 
reduced because of slow self-immolation if this allows 
clearance of circulating taxol linker prior to conversion 
to the active compound, taxol. However, slow self- 
immolation of taxol linker may also limit the anti-tumor 
efficacy of PROTAX. The solubilities of PROTAX and 
taxol in 1 96 (v/v) DMSO in PBS at 20 “C are -3Okg 
ml-’ and < 5 kg ml-‘, respectively (M.L.R., unpub- 
lished data). It mnv be possible to optimize the thera- 
peutic benefit of PROTAX and enhance the solubility 
by judicious modification of the linker. 
Effect of PROTAX on microtubule assembly 
Taxol promotec the polymerization of bovine brain 
tubulin 1211, whereas PROTAX has virtually no effect 
on the assembly of microtubules (Fig. 3). In contrast, 
PROTAX activated overnight in the presence of 
P-lactamnse has very similar activity to free tax01 in pro- 
moting microtubule assembly. Brief activation (15 min) 
of PROTAX with P-lactamase did not enhance its 
ability to promote tubulin polymerization (not shown). 
This \vas anticipated from the lack of microtubule- 
Clsscnibly activity of taxol linker (M.L.R.. unpublished 
data) and its slo~v conversion to tax01 (Fig. 2). 
Cytotoxicity of PROTAX 
PROTAX ic -lo-fold less toxic than taxol against the 
breast tumor cell line, SK-BR-3, following 6 h exposure 
to theqe cytotoxic agents (Fig. 4a). In contrast, in 
the presence of the targeting fusion protein, dsFv3- 
p-lactamase. the potency of PROTAX approaches that 
of free taxol for corresponding 6 h exposures. Following 
brief exposure (1 h) to dsFv3-P-lactamase the cytotoxic 
arti\rity of PROTAX against SK-BR-3 cells is enhanced 
to .I level that is approximately half that of taxol 
(Fig. 4b). This enhancement is greater than that antici- 
pated from the slow kinetics of the self-immolation reac- 
tion (Fig. 2). Enhanced cellular uptake of taxol-linker 
and taxol compared to PROTAX warrants investigation 
as a possible explanation for this observation. 
Significance 
The effkacy of taxol in breast and ovarian 
cancers has led to its approval for treatment of 
these diseases despite its poor solubility and 
numerous toxicities. The solubility of taxol has 
previously been enhanced by the synthesis of 
water-soluble derivatives [22-241 including pro- 
drugs [25] that are efficiently activated in human 
serum. Here we have extended the scope of taxol 
prodrugs by the synthesis of PROTAX, which is 
the first reported enzyme-activatable prodrug of 
taxol. Thus PROTAX is the first taxol prodrug 
that is potentially targetable to a tumor using an 
antibody-enzyme fusion protein. 
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Fig. 4. In vitro cytotoxic effect of taxol and PROTAX against SK- 
BR-3 cells. Tumor cells were incubated with taxol (0) or with 
PROTAX in the absence (0) or presence (0) of 180 nM dsFv3- 
p-lactamase for (a) 6 h or (b) 1 h at 37 “C. The cells were cultured 
in fresh media for a total culture time of 72 h prior to crystal violet 
staining. Data shown are the mean + SD of duplicate samples. 
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PROTAX comprises taxol linked by the C-2’ 
hydroxyl to a cephalosporin via an aminobutyryl 
linker-Tax01 is released from PROTAX following 
P-lactamase-mediated hydrolysis and self-immo- 
lation. PROTAX broadens the utility of cephems 
as triggers for prodrugs by demonstrating the 
ef&acy of coupling through a hydroxyl group on 
a drug and of using a self-immolative linker to 
synthesize a prodrug. 
PROTAX is -lo-fold less toxic than free taxol 
against SK-BR-3 cells in vitro, but is equally active 
following prolonged activation. In contrast, a 
related cephem prodrug of a vinca alkaloid is 
only five-fold less toxic than the parent free drug 
[S] against tumor cells in vitro but is highly efZca- 
cious in a tumor xenograft model in viva [3]. These 
data encourage the evaluation of the anti-tumor 
efEcacy of PROTAX in conjunction with the 
dsFv3-P-lactamase targeting fusion protein in vivo. 
Materials and methods 
Chemical synthesis 
2’-N-(Carbobenzyloxy)-y-aminobutyryl taxol (compound 2) 
N-CBz-y-aminobutyric acid (50 mg, 0.21 mmol) and di- 
cyclohexylcarbodiimide (40 mg, 0.19 mmol) were added to a 
solution of taxol (compound 1, Fluka, Ronkonkoma, NY) 
(50 rng, 0.05Y rnrnol) in anhydrous acetonitrile (10 ml).The reac- 
tion mixture was stirred at room temperature (r.t.) for 48 h.The 
solvent was evaporated and product dissolved with 
EtOAc/hexane (55:45) and purified by flash chromatography to 
give compound 2 (42 mg, 66 ‘%I): white solid; R, = 0.37 
(EtOAc/hexane, 60:40). All ‘H NMR spectra were obtained 
using aVarianVXR-300 spectrometer at 25 “C using L)MSO-DA 
(contains 0.05 % (v/v) TMS) ‘, 15 a solvent. proton shift assigIi- 
merits were facilitated by ‘H-‘H correlated spectroscopy 
(COSY). 9.10 (lH, d, ‘ZIHH z8.i Hz, C3’HNH), 8.0-7.0 (20H, 
m,Ar-H),7.10 (lH,CbzNH),6.28 (lH,s, Cl+H), 5.83 (lH,m, 
Cl3-H), 5.54 (IH, d, ‘JHH=8.XHz), 5.42 (IH, d, ‘tjHH=7.1Hz, 
C2-H), 5.35 (lH, C2’-H), 4.W (2H, s, PhCH,O), 4.91 (IH, d, 
.jJHH=8.31 Hz, CS-H), 4.11 (lH, m, C7-H), 3.02 (2H, m, 
C20-H), 3.5’) (lH, d, ‘J 
CbzNHCH,), 2.42 (2H, t. ~~,‘:l~~~~H~~~~~2~~~~~ 
(4H, m, C6-H, CH,COOC4), 2.10 (3H, s, Ck:,COOCl0): T.78 
(3H, Cl%H), 1.70 (IH, Cl4-H), 1.67 (2H, 111, 
CbzNHCH,CH2), 1.50 (5H, m, C6-H, Cl’)-H, C14-H), 1.03 
(3H, s, Cl&H), 1.00 (3H, s, C17-H). FAB HRMS rrz/e 
1073.4284 (M+H+) calculated for C,,H,,N,O,,: 1073.4313. 
2 ‘-(y-Aminobutyryl) taxol formate (compound 3) 
CBz-aminobutyryl taxol (compound 2) (68 rng, 0.063 mmol) 
was dissolved in MeOH (50 ml). F orrnic acid (3.5 ml) plus a 
catalytic amount of 10 %I Pd/C were then added and the reac- 
tion mixture stirred at r.t. for 4 h.The resulting mixture was fi- 
tered and concentrated under vacuum. The resulting residue 
(50 mg compound 3) was then used immediately for the 
synthesis of compound 5. 
Cephalothin-2’.(y-aminobutyryl) taxol prodrug 
(compound 5) 
Compound 3 (50 mg) was resuspended in tetrahydrofuran 
(40 ml) and compound 4 (100 mg, 0.19 nunol, synthesized as 
previously described 171) was added to the solution followed by 
NaHCO, (0.1 N, 8 ml).After stirring at r.t. for 15 rnin the reac- 
tion was terminated with HCl (0.1 N, Y ml). The product was 
extracted with EtOAc and purified on a C,, column (Rainin, 
Microsorb X0-220Cj) with 40 ‘I/ ( / ) 0 v v acetonitrile, 0.1 ‘%, (v/v) 
trifluoroacetic acid (TFA) in Hz0 as the mobile phase. The 
eluted HPLC pool was lyophilized to give the taxol prodrug, 
compound 5 (68 mg, 81 ‘%I): white solid. ‘H NMR spectra were 
obtained as described above: Y.31 (lH, d, 1J1,,r=7.3 Hz. 
C3’HNH), 8.0-7.0 (16H. m, PhH, SCH), 7.1’) (lH, 
CH,OCNH), 6.96 (2H, m, SCHCHCH), 6.28 (1 H, s, Cl&H), 
5.80 (ZH, m, CL-H), 5.53 (IH, d, .?rHH=8.7H2, C3’-H), 5.40 
(1 H, d, iJ,+, =&YHz, <:2-H), 5.34 (lH, C2’-H), 5.07 (lH, cyclo- 
NCOCHCH), 4.92 (2H, s, CH,OCONH), 4.90 (lH, C5-H), 
4.61 (IH, cycle-NCOCHCH), 4.09 (ZH, m, C7-H), 4.00 (2H. 
111, C20-H), 3.90 (1 H, d, ?JHH= 15.5Hz, S(O)CHHC),3.78 (lH, 
d, ‘JHH= 155Hz, S(O)CHHC), 3.50 (IH, C3-H), 2.97 (2H. m, 
OCNHCH,), 2.40 (2H, t, 3JHH=7 Hz, CH,COOC2’), 2.22 (I H, 
CO-H), 2.22 (3H, s, CH,COOC4), 2.09 (3H, 5, CH,COOClO), 
1.77 (2H, 111, CZ 14-H). 1.64 (2H, m, CH,CH,COOC”), I .4Y 
(IH, C&H), 1.4’) (3H. s, ClY-HI), 1.01 (3H,i, Clh-H), O.YY 
(3H, s, C17-H); FAB HRMS W/C 1335.4006 calculated 
for C~,hH70N~022SL: 1335.4002. 
Expression and purification of P-lactamase RTEM- 1 and 
dsFv3-/3-lactamase fusion protein 
The dsFv3-P-lactamase f&ion protein and p-lactamase were 
secreted from E. roli strain 27C7 containing expression plasnuds 
pRZ1 and pRZ3, respectively, grown for 32 h at 30 “C in an 
aerated IO liter fermentor and purified as previously described 
[7]. Purified proteins were buffer exchanged into PBS and their 
concentration estimated from the absorbance at 280 mn (E,#(,): 
dsFv3-P-lactarnase, eZX,, = 1.2 x 10’ cm-’ Mm’ [7]; p-lactamase 
7” 
= 2.Y4 x IO1 cn-’ M-’ [28]. Purified proteins were flash 
rozen in liquid nitrogen and stored at -70 “C until required. 
Kinetic procedure 
Kinetic assays were performed in 10 ‘%I (V/V) DMSO in PBS, 
pH 7.4, at (25 & 0.2) ‘C using either 0.2 cm or 1 cm path 
length quartz cuvettes and a Kontron Uvikon 860 spectro- 
photometer. Initial rates of hydrolysis of 8-34 p,M PROTAX 
with 4.76 nM dsFv3-P-lactamase or 1 l-l 12 PM PROTAX 
with 3.7 nM p-lactamase were determined by monitoring the 
reduction in absorbance at 260 nm over -2.5 min and using the 
experimentally determined extinction coefficient for 
PROTAX: AE,~~,~ = 1.03 x 101 cm-.’ Mm’. Estimates of kLlt/K,,,, 
ratios were made from the slope of the linear plots of ‘initial 
reaction rates versus substrate concentrations 1291 using a non- 
linear least squares fit (KaleidaGraph version 3.0.5, Synergy 
Software, Reading, PA). 
Microtubule assembly assay 
Bovine brain tub&n (1 mg m-l; Cytoskeleton, Santa Barbara, 
CA) was incubated with 11 p,M taxol, or 11 FM PROTAX 
before or after activation with 180 nM P-lactamase for 18 h, or 
buffer alone (80 mM PIPES (pH 6.8), 1 mM MgCI,, 1 n1M 
EGTA, 1 %) (v/v) DMSO) at (35 2 1) “C. Polymerization of 
tubuhn way monitored by following the absorbance at 340 nm. 
In vitro cytotoxicity assay 
SK-BR-3 breast carcinoma cells (ATCC, Rockville, MI)) were 
cultured in Dulbecco’s modified Eagle’s medium/Ham’s nutrient 
F-12 (50:50) supplemented with 2 mM glutamine, 100 units 
in-’ penicillin, 100 p,g nil-’ streptomycin (Gibco BRL, Grand 
Island, NY), and 10 ‘%, bovine fetal serum (Hyclone, Logan, UT) 
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,lt 37 C. 5 ‘XI CO, and pH 7-7.1. Cells were seeded at 1.2 x 10’ 
cell\ per \vell in ‘IO-\vell tissue culture plate5 (Becton IIickinton, 
Franklin Lakm, NJ) and allowed to attach for a n~inimum of 4 h. 
Te\t nledia consisting of O-l .2 p,M tasol or O-1.2 p,M 
I’I<<OTAX and 5 0.1 ‘% (v/v) I>MSO in the absence or presence 
of 180 nM d\Fv3-P-l.lct,lnl‘lse \\;a\ added to the wells. Plates 
\xwe mcubated at 37 “(1, 5 ‘%I CO1, for 21 h, washed twice with 
\vGjrlll tnrdium. and incubated for <I further 1X h.The assay was 
terminated by staining \vith 0.5 ‘%I (xv/v) crystal violet in 
McOH, and the abyorbancc was read at 540 nm (SLT 340 
ATI’<: pl.lte reader. SLT Lab Instrunlent~, Salzburg,Austria).Ver) 
Grnll~~l- result\ \xe~-e obtained using methods that detect only 
viable cells: ,Il.m~x blue assay, MTT staining, or direct cell count- 
ing (dx.1 not \ho\vn). No cnhmccment of the cytotosic activig 
of t.rxol .lgal~~st SK-BI<-3 cell\ \V.IS observed in the presence 
ii\Fv3~P-lact;lm,l~~ (ct.&t not sho~vn). 
Supplementary material available 
Supplrtnentary Inaterials include 1 II and 3D NMK spectra for 
compo~~nds 2 ,111d 5 plus HPLC tl-aces for compound 5. 
.-ic-krl~~rr~/[,r!\l~~~~~~lrs: We thank Kathy O’Connell for FAU HKMS 
dlt.1 ,lnd John 13urnicr ,md Paul Godowski for support. 
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